The centre will provide an opportunity for researchers from distinct disciplines across the University and beyond to come together with the common aim of exploring all areas of biology and medicine as the basis for these diseases collaboratively, to accelerate discoveries in these fields.
Cellular metabolism underpins all of human physiology and disease. Disturbance of cellular metabolism is a hallmark of many diseases including stroke, obesity, cancer, diabetes, and inherited metabolic disorders, as well as of physical and cognitive decline during aging.
MCCM is jointly directed by Professor Michael Lisanti and Professor Paul Townsend, from the University’s Faculty of Medical and Human Sciences. Professor Lisanti is the director of the Breakthrough Breast Cancer Research Unit within the Manchester Cancer Research Centre, a partnership between The University, The Christie NHS Foundation Trust and Cancer Research UK. His group focuses on metabolism and the ‘Reverse Warburg Effect’ to improve the treatment and prevention of breast cancer.
Professor Lisanti said: “The goal of MCCM is to enable cutting-edge research across diverse academic disciplines within this common area of interest. The Centre will bring together leading scientists and clinicians in metabolism research, drawing on expertise on a local, national, and international stage, in academia and industry, to enhance success through collaboration.”
Professor Townsend, Associate Dean for Business Engagement and research professor in the Institute of Cancer Sciences, added: “The knowledge gained will form the basis for the development of new means of diagnosis, prevention and personalised treatment for metabolic disorders like obesity to improve health and quality of life nationally, and globally.”
Partnership with clinical collaborators and industry will accelerate research from bench to diagnosis and bedside care. Initial partners of MCCM will include the University Faculties of Life Sciences and Engineering and Physical Sciences, CADET (Centre for Advanced Discovery and Experimental Therapeutics), Manchester Cancer Research Centre, Manchester Collaborative Centre for Inflammation Research, Cancer Research UK’s Manchester Institute, multinational Pharma, SMEs within the N8 region and beyond, and the Manchester Academic Health Science Centre (MAHSC).Professor Lisanti is listed amongst the Top 100 most-cited researchers in biochemistry and biology, and was previously founder and director of the Division of Basic and Translational Science, and Stem Cell Biology and Regenerative Medicine Centre at the Kimmel Cancer Centre, Thomas Jefferson University. His research has broad implications for understanding the mechanisms underlying chronological ageing and the prevention of aging-associated diseases including cancer, atherosclerosis, and neuro-degeneration.
Professor Townsend is an expert in apoptosis, cell stress responses and gene regulation. Cofounder of Oxford-based pharmaceutical company Karus Therapeutics, he has extensive experience in IP generation, protection, consultancy and enterprise activities. One major area of success has been as lead Business Fellow in Medicine, and the most prolific business fellow in the original London Technology Network portfolio, helping to foster links between industrial partners and academics. Professor Townend’s background makes him well positioned at the interface between MCCM and industrial collaborators.
Recent University of Manchester recruit and world-renowned scientist Professor Sir Salvador Moncada, who received a knighthood in the 2010 New Year Honours for services to science, will also lend strategic direction to the Centre.
Notes for editors
Photograph of Professor Lisanti and Professor Townsend in one of the laboratories that will form part of the MCCM available on request later today.
For further information, please contact Alison Barbuti in The University of Manchester Press Office on 0161 275 8383 or email email@example.com.
MCCM is to be formally launched with an inaugural showcase event on 14 January 2014
The University of Manchester
The University of Manchester, a member of the Russell Group, is one of the largest and most popular universities in the UK. It has 20 academic schools and hundreds of specialist research groups undertaking pioneering multi-disciplinary teaching and research of worldwide significance. According to the results of the 2008 Research Assessment Exercise, The University of Manchester is one of the country’s major research institutions, rated third in the UK in terms of ‘research power’. The University has an annual income of £807 million and is ranked 40th in the world and fifth in the UK for the quality of its teaching and impact of its research.
About Breakthrough Breast Cancer:
• Breakthrough Breast Cancer is the UK’s leading breast cancer charity dedicated to saving lives through improving early diagnosis, developing new treatments and preventing all types of the disease.
• The need for Breakthrough Breast Cancer’s work has never been greater. Breast cancer is still the most commonly diagnosed cancer in the UK, affecting 50,000 women every year and killing 1,000 every month.
• Breast cancer is not yesterday’s problem; it’s a disease that affects more women every year. Breakthrough Breast Cancer is working harder than ever before to stop women dying from the disease.
• The charity funds 25% of the breast cancer research in the UK, campaigns to ensure survival rates are among the best in the world and educates women to recognise the signs and symptoms of the disease.
• Breakthrough Breast Cancer’s vision is a world freed from breast cancer.
• For more information go to breakthrough.org.uk